Improved outcomes with surgery compared to radiofrequency ablation in the treatment of resectable hepatocellular carcinoma

Eur J Gastroenterol Hepatol. 2019 Nov;31(11):1397-1402. doi: 10.1097/MEG.0000000000001416.

Abstract

Background: While overall cancer incidence and mortality have decreased over the last decade, hepatocellular carcinoma (HCC) cases have increased sharply.

Objective: This study set out to evaluate the utility of surgery for resectable single tumor HCC in this setting.

Patients and methods: This study analyzed the National Cancer Database, selecting all patients with a histological diagnosis of HCC and an isolated tumor (≤5 cm) treated with radiofrequency ablation (RFA) or surgical resection.

Results: A total of 7821 patients were identified for this study. In the patients with a single tumor up to 3 cm, 40% had a surgical resection and 60% had RFA. In the group with a tumor 3.01-5 cm, 62% had a surgical resection and 38% had RFA. Patients with a single tumor up to 5 cm had a 3-year survival of 60% after resection compared to 42% with RFA. When the patients were split into those with a tumor up to 3 cm or a tumor 3.01-5 cm, there was a survival benefit in the surgical resection cohort.

Conclusion: Surgical resection may be underutilized in the USA for resectable HCC, especially in patients with a tumor up to 3 cm.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Carcinoma, Hepatocellular / pathology
  • Carcinoma, Hepatocellular / surgery*
  • Catheter Ablation / methods*
  • Female
  • Hepatectomy / methods*
  • Humans
  • Kaplan-Meier Estimate
  • Liver Neoplasms / pathology
  • Liver Neoplasms / surgery*
  • Male
  • Middle Aged
  • Survival Rate
  • Tumor Burden